How to Avoid US FDA Warning Letters in Clinical Studies
Health Decisions CEO Dr. Michael Rosenberg explains how adaptive monitoring can be a better way of tracking investigative site quality and performance.
People Spotlight: Bryan Minihan, Health Decisions CTO
Armed with 15 years of technology experience, Bryan Minihan has been tapped to lead the technology function of clinical research firm Health Decisions. With experience at companies such as...
FDA drafts adaptive clinical trial design guidance
FDA drafts adaptive clinical trial design guidance The FDA’s draft guidance on adaptive design in clinical trials is a balanced, practical publication, according to the EVP of a...
Rosenberg: Make Adaptive Clinical Trials More Agile
Companies that actively embrace adaptive methods will be tomorrow's leaders in the biopharmaceutical industry, says Michael Rosenberg, president and CEO of Health Decisions, and author of the...
Congenix Joins Agile Clinical Network
In a drive to cut timelines and increase transparency for multinational trials, Congenix, a UK-registered CRO with expertise in conducting clinical trials in Russia and Eastern Europe, has joined...
Report offers tips to minimize risk and ensure trial success
According to a new white paper from global CRO Health Decisions, "if a drug works, there should be no reason for a clinical trial to fail," and the same could easily be said of a device trial. This...
Health Decisions builds network of international CROs to improve clinical trials research
Health Decisions, a full-service clinical research organization (CRO) specializing in adaptive solutions, is raising the standard of efficiency in global trials through its new, international CRO...
RFP Reform: The Problem With Getting What You Ask For
Although many pharma companies do not realize it, their RFPs block the path to greater success. Pharma companies and innovative CROs have a strong shared interest in refocusing procurement efforts...
Health Decisions Completes Enrollment In Phase II Flu Vaccine Trial
Health Decisions, a full-service clinical research organization (CRO) specializing in high-efficiency adaptive solutions, has completed enrollment for a phase II universal flu vaccine study three...
Peer Reviewed: International Express
The economic downturn has forced pharma companies large and small to re-examine many business practices. Boom times forgive inefficiency; recessions punish it without mercy. Continued reliance on...
